Delhi HC Refuses Interim Injunction in Semaglutide Patent Dispute

Introduction

On 2 December 2025 the Delhi High Court refused to grant an interim injunction sought by Danish pharmaceutical company Novo Nordisk against Dr Reddy’s Laboratories in relation to semaglutide, a high-value antidiabetic and weight-loss compound. The court observed that Novo Nordisk held two patents relating to the same compound and questioned the grant of exclusive interim relief on that basis. The decision is significant for patent enforcement strategy in India’s pharmaceutical sector, affecting how originator companies seek urgent remedies against generic manufacturers in fast-moving global markets.

Legal Background

The legal contest engages core principles of patent law — patentability, scope, and the doctrine against double patenting — and the procedural test for interim injunctions. In India, patent rights are conferred under the Patents Act, 1970 (as amended), with judicial guidance from decisions such as Novartis AG v Union of India (2013) on pharmaceutical claims and Section 64–66 principles for revocation and validity. The interim relief framework imports the familiar three-pronged American Cyanamid test (suitability of interlocutory relief pending trial: serious question to be tried; balance of convenience; and irreparable injury), applied by Indian courts to patent disputes. The doctrine of double patenting — preventing two patents for substantially the same invention to the same or related parties — has been developed in EU and Commonwealth jurisprudence and has recently featured in Indian adjudication when overlapping claims raise enforceability concerns. The Delhi High Court judgment in Novo Nordisk AS v Dr Reddy’s Laboratories Ltd (2 Dec 2025) is the immediate touchstone for this analysis.

Critical Analysis

On the facts reported, the court’s refusal of interim relief rested on two interlocking considerations: first, the existence of two patents held by Novo Nordisk for the same compound (semaglutide), and second, the equitable consequences of enforcing exclusivity where patent boundaries are contested. The preliminary double patenting question is legally material. If an originator holds multiple patents that effectively claim the same inventive contribution in different claim formulations, injunctions that protect one claim while another remains under challenge can produce overbroad exclusivity. Courts have been wary of such outcomes, mindful of public interest in access to medicines and the need to avoid chilling competition pending final adjudication.

Applying the American Cyanamid principles, the court appears to have found that there was no clear, pressing balance of convenience in favour of Novo Nordisk. The “serious question to be tried” on validity may have been present, but when the validity itself is complicated by overlapping patent rights, the risk of granting an injunction inconsistent with the ultimate resolution is heightened. Indian courts have previously balanced these factors with sensitivity to downstream consequences — see precedents where interim relief was denied or limited where monolithic exclusivity would be disproportionate (for example, cases referencing the Novartis litigation’s public policy context). International authorities, including EU practice on double patenting and EPO scrutiny (e.g., decisions addressing patent divisional claims and added-matter), counsel against extending provisional relief where the patent portfolio shows internal conflicts.

A further consideration is the adequacy of damages. High-value pharmaceutical products generate significant sales, and originators routinely argue that monetary compensation cannot compensate for market erosion and reputational harm. The Delhi court’s approach suggests it weighed whether Dr Reddy’s would be adequately compensable if found infringing — or conversely whether Novo Nordisk would be adequately protected by damages if the patents were later upheld. Where the contested patents overlap, a damages remedy may be an acceptable, less intrusive alternative to an injunction until validity and scope are conclusively determined.

It is important to note certain factual gaps in media reporting: the precise claims asserted, claim construction positions, timing of patent grants or divisionals, and market launch timelines are not fully articulated. Those facts would materially affect the interim calculus. For instance, an imminent launch with irreversible market penetration could tilt the balance differently than a distant or limited commercialisation plan.

Opinion & Outlook

The Delhi High Court’s decision signals judicial caution about immediate exclusionary relief in complex pharmaceutical patent portfolios. Practically, originator companies should recalibrate interim injunction strategies in India: ensure clear, non-overlapping claim charts; be prepared to demonstrate irreparable harm beyond market competition; and consider bond or escrow mechanisms to protect defendants against wrongful restraint. Generic manufacturers may see this as a permitting environment to continue launch preparations while legal disputes proceed, but litigation risk remains substantial where individual patent claims are cleanly asserted.

From a policy perspective, the judgment underscores the need for doctrinal clarity on double patenting under Indian law. The Patents Act and patent office practice would benefit from clearer rules on divisionals, claim scope consolidation, and guidance on when overlapping patents may be consolidated or limited. Legislatures and tribunals should also consider procedural innovations — expedited validity hearings in high-stakes pharmaceutical disputes — to reduce reliance on interlocutory equity.

On precedent, the court’s reliance on equitable balancing aligns with Commonwealth and EU approaches and preserves consistent judicial reluctance to grant sweeping provisional monopolies in the face of contested validity. If appealed, the Supreme Court of India could crystallise standards on double patenting and the evidentiary threshold for interim relief in multi-patent portfolios.

Conclusion

The Delhi High Court’s refusal of an interim injunction in the semaglutide dispute reflects a cautious, equity-driven approach to patent enforcement where overlapping patents raise substantive validity questions. For practitioners, the judgment is a reminder that patent enforcement strategy in India must address portfolio coherence, evidential depth, and alternative remedies; for policymakers, it highlights gaps in doctrinal clarity that merit legislative and procedural attention.